Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Nextcure Inc (NXTC)

Nextcure Inc (NXTC)
0.3410 x 20 0.4270 x 4
Post-market by (Cboe BZX)
0.4005 +0.0315 (+8.54%) 04/22/25 [NASDAQ]
0.3410 x 20 0.4270 x 4
Post-market 0.4005 unch (unch) 15:59 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.3751
Day High
0.4124
Open 0.4000
Previous Close 0.3690 0.3690
Volume 376,000 376,000
Avg Vol 263,755 263,755
Stochastic %K 53.60% 53.60%
Weighted Alpha -76.55 -76.55
5-Day Change +0.0885 (+28.37%) +0.0885 (+28.37%)
52-Week Range 0.2240 - 1.8199 0.2240 - 1.8199
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,350
  • Shares Outstanding, K 28,050
  • Annual Sales, $ 0 K
  • Annual Income, $ -55,650 K
  • EBIT $ -60 M
  • EBITDA $ -58 M
  • 60-Month Beta 0.89
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.15
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.98
  • Most Recent Earnings $-0.41 on 03/06/25
  • Next Earnings Date 05/01/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.40
  • Number of Estimates 2
  • High Estimate -0.38
  • Low Estimate -0.42
  • Prior Year -0.61
  • Growth Rate Est. (year over year) +34.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2240 +78.79%
on 04/10/25
Period Open: 0.5700
0.6679 -40.04%
on 03/25/25
-0.1695 (-29.74%)
since 03/21/25
3-Month
0.2240 +78.79%
on 04/10/25
Period Open: 0.7965
0.9000 -55.50%
on 01/23/25
-0.3960 (-49.72%)
since 01/22/25
52-Week
0.2240 +78.79%
on 04/10/25
Period Open: 1.6100
1.8199 -77.99%
on 07/16/24
-1.2095 (-75.12%)
since 04/22/24

Most Recent Stories

More News
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

NXTC : 0.4005 (+8.54%)
NextCure Provides Business Update and Reports Full Year 2024 Financial Results

NXTC : 0.4005 (+8.54%)
Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe

KURA : 6.31 (+2.10%)
SHPH : 0.2511 (+0.12%)
LPTX : 0.3860 (+7.34%)
NXTC : 0.4005 (+8.54%)
ACET : 0.5817 (+2.34%)
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

NXTC : 0.4005 (+8.54%)
NextCure, Inc. Announces FDA Acceptance of IND Application for Phase 1 Trial of B7-H4-targeting ADC LNCB74

NextCure’s IND for LNCB74, a B7-H4-targeting ADC, has been accepted for a Phase 1 cancer trial.Quiver AI SummaryNextCure, Inc. has announced that the FDA has accepted its Investigational New Drug application...

NXTC : 0.4005 (+8.54%)
NextCure Announces Acceptance of IND Application for LNCB74

NXTC : 0.4005 (+8.54%)
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

NXTC : 0.4005 (+8.54%)
NextCure, Inc. Reports Promising Preclinical Data for NC605 in Osteogenesis Imperfecta Treatment

NextCure presented promising preclinical data on NC605, an antibody that enhances bone quality in Osteogenesis Imperfecta.Quiver AI SummaryNextCure, Inc. has announced promising preclinical data showcasing...

NXTC : 0.4005 (+8.54%)
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

NXTC : 0.4005 (+8.54%)
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

NXTC : 0.4005 (+8.54%)

Business Summary

NextCure Inc. is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company's product candidate consists of NC318 and NC410 which are in clinical stage. NextCure Inc. is based in Beltsville, Maryland....

See More

Key Turning Points

3rd Resistance Point 0.4542
2nd Resistance Point 0.4333
1st Resistance Point 0.4169
Last Price 0.4005
1st Support Level 0.3796
2nd Support Level 0.3587
3rd Support Level 0.3423

See More

52-Week High 1.8199
Fibonacci 61.8% 1.2103
Fibonacci 50% 1.0220
Fibonacci 38.2% 0.8336
Last Price 0.4005
52-Week Low 0.2240

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro